Literature DB >> 17118758

Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.

Ken-ichi Minehata1, Masaki Takeuchi, Yoko Hirabayashi, Tohru Inoue, Peter J Donovan, Minoru Tanaka, Atsushi Miyajima.   

Abstract

Bone marrow (BM) functions as the primary hematopoietic tissue throughout adult life by providing a microenvironment for the proliferation, differentiation, and retention of hematopoietic stem cells and progenitors. We describe novel roles for oncostatin M (OSM) in the BM hematopoietic microenvironment. Hematopoietic progenitor activity in OSM-deficient mice was reduced in BM but elevated in the spleen and peripheral blood. The level of circulating granulocyte colony-stimulating factor (G-CSF) was increased, whereas that of stromal cell-derived factor 1 (SDF-1) was decreased in OSM-deficient mice. Moreover, the ability of OSM-deficient BM stromal cells to support hematopoiesis in vitro was significantly reduced. These results indicate that OSM plays a unique role in hematopoiesis by maintaining the proper microenvironment for BM hematopoiesis; it also retains hematopoietic progenitors in BM by regulating G-CSF and SDF-1 levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118758     DOI: 10.1532/IJH97.06090

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  43 in total

1.  Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Authors:  Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

2.  In vitro expansion of murine multipotential hematopoietic progenitors from the embryonic aorta-gonad-mesonephros region.

Authors:  Y Mukouyama; T Hara; M Xu; K Tamura; P J Donovan; H Kim; H Kogo; K Tsuji; T Nakahata; A Miyajima
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

3.  Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells.

Authors:  T J Brown; M N Lioubin; H Marquardt
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

4.  Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells.

Authors:  K Hattori; B Heissig; K Tashiro; T Honjo; M Tateno; J H Shieh; N R Hackett; M S Quitoriano; R G Crystal; S Rafii; M A Moore
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

6.  Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis.

Authors:  T Kinoshita; T Sekiguchi; M J Xu; Y Ito; A Kamiya; K Tsuji; T Nakahata; A Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

7.  Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway.

Authors:  A Yoshimura; M Ichihara; I Kinjyo; M Moriyama; N G Copeland; D J Gilbert; N A Jenkins; T Hara; A Miyajima
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

8.  Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.

Authors:  L B To; K M Shepperd; D N Haylock; P G Dyson; P Charles; D L Thorp; B M Dale; G W Dart; M M Roberts; R E Sage
Journal:  Exp Hematol       Date:  1990-06       Impact factor: 3.084

9.  Molecular cloning and structure of a pre-B-cell growth-stimulating factor.

Authors:  T Nagasawa; H Kikutani; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

10.  Thrombocytopoietic properties of oncostatin M.

Authors:  P M Wallace; J F MacMaster; J R Rillema; J Peng; S A Burstein; M Shoyab
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  15 in total

1.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

2.  Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.

Authors:  Gregor Hoermann; Sabine Cerny-Reiterer; Andrea Perné; Miriam Klauser; Konrad Hoetzenecker; Katharina Klein; Leonhard Müllauer; Marion Gröger; Sebastian M B Nijman; Walter Klepetko; Peter Valent; Matthias Mayerhofer
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

3.  Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis.

Authors:  Hendra Setiadi; Tadayuki Yago; Zhenghui Liu; Rodger P McEver
Journal:  Blood Adv       Date:  2019-01-22

4.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

5.  Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications.

Authors:  Frédéric Torossian; Bernadette Guerton; Adrienne Anginot; Kylie A Alexander; Christophe Desterke; Sabrina Soave; Hsu-Wen Tseng; Nassim Arouche; Laetitia Boutin; Irina Kulina; Marjorie Salga; Beulah Jose; Allison R Pettit; Denis Clay; Nathalie Rochet; Erica Vlachos; Guillaume Genet; Charlotte Debaud; Philippe Denormandie; François Genet; Natalie A Sims; Sébastien Banzet; Jean-Pierre Levesque; Jean-Jacques Lataillade; Marie-Caroline Le Bousse-Kerdilès
Journal:  JCI Insight       Date:  2017-11-02

6.  Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization.

Authors:  Kavita Bisht; Crystal McGirr; Seo-Youn Lee; Hsu-Wen Tseng; Whitney Fleming; Kylie A Alexander; Taichi Matsumoto; Valérie Barbier; Natalie A Sims; Gerhard Müller-Newen; Ingrid G Winkler; Halvard Bonig; Jean-Pierre Lévesque
Journal:  Leukemia       Date:  2021-09-13       Impact factor: 11.528

7.  Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner.

Authors:  Tania J Fernandes; Jason M Hodge; Preetinder P Singh; Damien G Eeles; Fiona M Collier; Ian Holten; Peter R Ebeling; Geoffrey C Nicholson; Julian M W Quinn
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

8.  Oncostatin M decreases interleukin-1 β secretion by human synovial fibroblasts and attenuates an acute inflammatory reaction in vivo.

Authors:  Aline Dumas; Stéphanie Lagarde; Cynthia Laflamme; Marc Pouliot
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

9.  Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis.

Authors:  Fumi Sato; Yuichiro Miyaoka; Atsushi Miyajima; Minoru Tanaka
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

10.  In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.

Authors:  Juliet Reid; Stefano Zamuner; Ken Edwards; Sally-Anne Rumley; Katherine Nevin; Maria Feeney; Chiara Zecchin; Disala Fernando; Nicolas Wisniacki
Journal:  Br J Clin Pharmacol       Date:  2018-07-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.